ClinicalTrials.gov
ClinicalTrials.gov Menu

MR-Lymphography and Lymph Node Staging in Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00185029
Recruitment Status : Unknown
Verified September 2005 by Radboud University.
Recruitment status was:  Active, not recruiting
First Posted : September 16, 2005
Last Update Posted : September 16, 2005
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University

Brief Summary:

This proposal is targeted at all patients with prostate cancer who are candidates for either curative surgery or curative radiotherapy in whom lymph node staging is indicated. Recently, it has been shown, that in patients with PSA <10 ng/ml and Gleason score < 7 the risk of lymph node metastases is low. Therefore, unnecessary PLND and non-invasive imaging can be avoided safely in this group. PLND is nowadays performed only in patients with intermediate or high risk for nodal metastases. Thus the subgroup of patients targeted in this study consists of patients with prostate cancer with a PSA >10 ng/ml and Gleason score > 6.

  • If the high sensitivity (90%) and negative predictive value (96%) of MRL can be validated in the 8 participating centres, in patients with a negative MRL invasive PLND may be avoided.
  • In patients with a positive MRL with enlarged nodes (larger than 8 mm) histological diagnosis may be obtained by imaged guided biopsy, and thus also in these patients avoid PLND. A limitation of image guide biopsy, however, is the 30% false negative rate. [Barentsz, Oyen, Wolf]
  • In patients with positive small nodes (smaller than 8 mm) the urologist may, focussed by the MRL findings of a positive node outside his “surgical field-of-view”, extend his dissection, and thus improve his accuracy.
  • Based on the expected higher sensitivity of MRL this technique will completely replace CT-scanning.

Condition or disease Intervention/treatment Phase
Prostatic Neoplasms Lymphatic Metastasis Procedure: Ferumoxtran-10 enhanced MRI (MRL) Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Enrollment : 396 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer?
Study Start Date : April 2002
Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources




Primary Outcome Measures :
  1. Primary outcome parameters concern accuracy sensitivity, specificity, PPV and NPV of both MRL and CT

Secondary Outcome Measures :
  1. Secondary outcome measures are costs per patient for each strategy. Besides this, quality of life after 6 months of follow up will be part of the analysis.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • prostate cancer
  • PSA > 10 or Gleason > 6 or T3 tumor
  • adult male
  • scheduled for lymphadenectomy
  • written informed consent

Exclusion Criteria:

  • Patient having undergone chemotherapy or radiotherapy of the pelvic area
  • patient having undergone resection of the pelvic tumor with lymphadenectomy
  • Patient included in another trial involving an investigational drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00185029


Locations
Netherlands
NKI AVL
Amsterdam, Netherlands, 1066 CX
Catharina Hospital
Eindhoven, Netherlands, 5602 ZA
Ziekenhuis Zeeuws-Vlaanderen
Terneuzen, Netherlands, 4535 PA
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Jelle Barentsz, Phd MD Radboud University

Publications of Results:
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00185029     History of Changes
Other Study ID Numbers: sinerem1
945-02-051
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: September 16, 2005
Last Verified: September 2005

Keywords provided by Radboud University:
prostate
ferumoxtran-10
lymph nodes
USPIO

Additional relevant MeSH terms:
Prostatic Neoplasms
Lymphatic Metastasis
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes